A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.
We previously reported that a vaccine composed of liposome-mannan complexes of Candida albicans (L-mann) stimulates mice to produce protective antibodies against disseminated candidiasis. An immunoglobulin M (IgM) monoclonal antibody (MAb), B6.1, specific for a beta-1,2-mannotriose in the complexes protects against the disease, whereas MAb B6 does not. In the present study, the vaccine and MAbs B6.1 and B6 were tested for the ability to protect against Candida vaginal infection, established by intravaginal (i.vg.) inoculation of yeast cells in mice maintained in pseudoestrus. Fungal CFU in each vagina was determined to assess the severity of infection. Mice vaccinated before infection developed about 62% fewer vaginal CFU than nonimmunized controls. Naive mice that received polyclonal antiserum (from vaccinated mice) i.vg. before infection had 60% fewer CFU than controls. The serum protective factor was stable at 56 degreesC, but C. albicans cells absorbed this factor. Mice given MAb B6.1 i.vg. after infection was established had fewer Candida CFU in vaginal tissue than control mice given buffer instead of antibody. MAbs B6.1 and B6 given intraperitoneally before infection protected mice, but MAbs preabsorbed with yeast cells did not. MAb B6.1 also protected against C. tropicalis vaginal infection, but MAb B6 did not. The protective activities of MAbs B6.1 and B6 appeared to be specific because an irrelevant IgM carbohydrate-specific MAb and an irrelevant IgG protein-specific MAb were not protective; also, MAb B6.1 did not affect development of vaginal chlamydial infection. These studies show that an appropriate antibody response, or administration of protective antibodies, can help the host to resist Candida vaginal infection.
Han
Y
Y
Department of Microbiology, Montana State University, Bozeman, Montana 59717-3520, USA.
Morrison
R P
RP
Cutler
J E
JE
D000818:Animals; D000908:Antibodies, Fungal / Q000032:analysis; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002181:Candidiasis, Vulvovaginal / Q000517:prevention & control*; D005260:Female; D005657:Fungal Vaccines / Q000627:therapeutic use*; D007113:Immunity, Innate; D007116:Immunization, Passive; D008351:Mannans / Q000276:immunology / Q000627:therapeutic use*; D051379:Mice; D013045:Species Specificity; D014611:Vaccination
D000908:Antibodies, Fungal; D000911:Antibodies, Monoclonal; D005657:Fungal Vaccines; D008351:Mannans